Minghui Pharmaceutical Announces Promising Initial Results from Phase I Clinical Trial of MHB039A, a Novel PD-1 x VEGF Bispecific Antibody, in Patients with Relapsed/Refractory Solid Tumors
Press Releases
Minghui Pharmaceutical, Inc.  
November 6, 2024

Minghui Pharmaceutical Announces Promising Initial Results from Phase I Clinical Trial of MHB039A, a Novel PD-1 x VEGF Bispecific Antibody, in Patients with Relapsed/Refractory Solid Tumors

SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company focused on developing transformative medicines in immunology and oncology, today announced initial results from its Phase I

logo salamanca press

Salamanca Press

Local & Social